Antithymocyte immunoglobulin (rabbit)
- Generic Name
- Antithymocyte immunoglobulin (rabbit)
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 308067-60-9
- Unique Ingredient Identifier
- D7RD81HE4W
- Background
Rabbit anti-thymocyte globulin. Thymoglobulin is a polyclonal antibody that suppresses certain types of immune cells responsible for acute organ rejection in transplant patients. Thymoglobulin is a mixture of antibodies intended to bind to various cell surface antigens. The most common mode of action of Thymoglobulin is via selective depletion of T-cells.
- Indication
For prevention of renal transplant rejection
- Associated Conditions
- Rejection Acute Renal
- Associated Therapies
- -
Stem Cell Transplantation for Stiff Person Syndrome (SPS)
- Conditions
- Interventions
- First Posted Date
- 2014-11-04
- Last Posted Date
- 2021-01-27
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 23
- Registration Number
- NCT02282514
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
Transplantation of Partially Mismatched Related or Matched Unrelated Bone Marrow for Patients With Refractory Severe Aplastic Anemia
- First Posted Date
- 2014-08-25
- Last Posted Date
- 2023-03-10
- Target Recruit Count
- 18
- Registration Number
- NCT02224872
- Locations
- 🇺🇸
The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸Medical College of Wisconsin/Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States
Belatacept Compared to Tacrolimus in Deceased Donor Renal Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2014-06-02
- Last Posted Date
- 2021-02-10
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 57
- Registration Number
- NCT02152345
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- First Posted Date
- 2014-05-21
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 70
- Registration Number
- NCT02143830
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Regimen Optimization Study
- Conditions
- Interventions
- First Posted Date
- 2014-05-13
- Last Posted Date
- 2021-06-22
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 58
- Registration Number
- NCT02137239
- Locations
- 🇺🇸
Emory Univeristy, Atlanta, Georgia, United States
🇺🇸University Of Illinois, Chicago, Illinois, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Single Dose rATG for Renal Allograft Rejection
- First Posted Date
- 2014-04-03
- Last Posted Date
- 2020-09-03
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 30
- Registration Number
- NCT02102854
- Locations
- 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant
- First Posted Date
- 2014-03-12
- Last Posted Date
- 2019-02-22
- Lead Sponsor
- Ronaldo de Matos Esmeraldo, MD
- Target Recruit Count
- 120
- Registration Number
- NCT02084446
- Locations
- 🇧🇷
Hospital Geral de Fortaleza, Fortaleza, Ceará, Brazil
Nonmyeloablative Conditioning and Transplantation for Patients With Refractory Systemic Lupus Erythematosus (SLE)
- First Posted Date
- 2014-03-06
- Last Posted Date
- 2019-10-02
- Target Recruit Count
- 1
- Registration Number
- NCT02080195
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Different Doses of Anti-thymocyte Globin to Treat Child Severe Aplastic Anemia
- First Posted Date
- 2013-11-28
- Last Posted Date
- 2013-12-03
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 100
- Registration Number
- NCT01997372
- Locations
- 🇨🇳
Department of Pediatrics, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
Preemptive Therapy of GVHD
- First Posted Date
- 2013-11-26
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- University of Calgary
- Target Recruit Count
- 70
- Registration Number
- NCT01994824
- Locations
- 🇨🇦
Alberta Health Services-CancerControl / University of Calgary / University of Alberta (Edmonton), Calgary, Alberta, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.